SEC Form 4 · accession 0001192482-18-000331
Zynerba Pharmaceuticals, Inc. · ZYNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth I Moch
Director
Period of report
Jul 2, 2018
Accepted (ET)
Jul 3, 2018 · 3:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621443
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $9.70 | Jul 2, 2018 | A | 952 | A | Jul 2, 2018 | Jul 2, 2028 | Common Stock | 952 | 952 | D |
Explanation of responses
- F1This option was issued to the reporting person pursuant to the Zynerba Pharmaceuticals, Inc. Non-Employee Director Compensation Policy in lieu of cash retainer of $5,937.50.